Key facts
- It has raised $40.0M; the latest was Later Stage VC ($10.0M) in Jan 2026.
- Notable investors include Clean Energy Finance, Ellerston Capital, TWIYO Capital & Advisory, Agronomics, David Shein — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for All G
- ·The full record, as it builds
Funding rounds
No funding rounds for All G are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About All G
Developer of recombinant human and bovine milk proteins designed for business-to-business supply to the infant formula industry. The company's pipeline includes high-value proteins such as lactoferrin and other bio-equivalent components of human milk, supported by proprietary intellectual property and scalable casein micelle technology, enabling infant formula producers to align protein profiles more closely with human breast milk and expand applications in advanced nutrition.
- Sector
- Healthcare
- HQ
- Waterloo, Australia
- Founded
- 2020
- Employees
- 32
- Website
- allg.com/
- Ownership
- Privately Held (backing)
All G doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in All G shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on All G in its N-PORT filings yet. We sweep new filings monthly.